For Immediate Release s326

For Immediate Release MEDIA CONTACT: Carmen L. Wiley, Ph.D., DABCC, FACB Scientific Director PAML, LLC and PAML Ventures Phone: (509) 755-8554 E-mail: [email protected] PAML Partners with Verinata Health to Offer Prenatal Laboratory Test to Detect Genetic Abnormalities New Test Provides More Accurate Information, Earlier in Pregnancy

SPOKANE, Washington (September 24, 2013) – PAML, LLC, one of the nation’s leading laboratories, through a partnership with Verinata Health, an Illumina company, is now offering the verifi® prenatal test for all patients within the network desiring non-invasive prenatal testing to detect Down syndrome, Edwards syndrome, Patau syndrome and sex chromosome abnormalities, the most common genetic abnormalities tested for during pregnancy. The verifi® prenatal test is a blood test that analyzes genetic material (or cell-free DNA) naturally found in a pregnant woman’s blood to detect the most common fetal chromosome abnormalities. When ordered by a physician, the verifi® test can be offered to women at high risk of having a child with a disorder caused by an abnormal number of chromosomes as early as 10 weeks of pregnancy. The availability of the verifi® prenatal test represents a major advance in prenatal testing, providing pregnant women with genetic information about their fetus without the risk associated with invasive testing such as amniocentesis or chorionic villus sampling (CVS). The verifi® prenatal test offers improved sensitivity and specificity over traditional screening tests, and for the majority of high-risk women, provides reassurance that their fetus is not affected with the most common genetic aneuploidies. “We are pleased to offer our patients this new method of prenatal screening,” said Carmen L. Wiley, PhD, Chief Scientific Officer of PAML, LLC and PAML Ventures. “We believe that by adding this test to our prenatal care regimen, we will continue to provide the best patient care, minimizing the anxiety associated with the multi-step prenatal screening process for our high- risk patients.”

The verifi® prenatal test is covered as an in-network, contracted benefit with many national and regional payers. All tests will be run in Verinata Health’s CLIA-certified laboratory in California. Results are returned to the physician in three to six business days. While the verifi test does not replace invasive procedures, it may dramatically reduce the number of unnecessary invasive procedures performed.

About Pathology Associates Medical Laboratories, LLC PAML, LLC, a healthcare solutions company with a focus in diagnostics with a national corporate headquarters in Spokane, Washington is a recognized leader with innovations in clinical diagnostics. One of the top reference laboratories in the country, PAML, LLC is also considered an industry leader in joint venture partnerships with community-based hospitals because of their expertise in developing cutting-edge laboratory management systems, including state-of-the-art automation, and support services.